

The Virulence Index: A Metric for Quantitative Analysis of Phage Virulence

1 **Zachary Storms**

2 Chemical and Materials Engineering, University of Alberta,
3 Edmonton, AB, Canada
4 zstorms@ualberta.ca

5

6 **Matthew R. Teel**

7 Chemical and Materials Engineering, University of Alberta,
8 Edmonton, AB, Canada
9 teel@ualberta.ca

10

11 **Kevin Mercurio**

12 Chemical and Materials Engineering, University of Alberta,
13 Edmonton, AB, Canada
14 kmerc065@uottawa.ca

15

16 **Dominic Sauvageau***

17 Chemical and Materials Engineering, University of Alberta,
18 Edmonton, AB, Canada
19 dominic.sauvageau@ualberta.ca
20 1-780-492-8092

21

22 *** Correspondence:**

23 Dominic Sauvageau
24 dominic.sauvageau@ualberta.ca

25

26 **Running Title:** Phage Virulence Index

27

28 **Keywords:** bacteriophage infection, bacterial reduction curve, comparative virulence, virulence
29 quantification, quality control, high-throughput analysis.

30 **Authors Confirmation Statement**

31 ZS and DS designed experiments. ZS, MRT, and KM performed experiments and analyzed data. ZS,
32 MRT, and DS developed virulence metrics. ZS, MRT, and DS wrote the manuscript.

33

34 **Author Disclosure Statement**

35 No competing financial interests exist.

36

37 Abstract

38 **Background:** One of the main challenges in developing phage therapy and manufacturing phage
39 products is the reliable evaluation of their efficacy, performance and quality. Since phage virulence is
40 intrinsically difficult to fully capture, researchers have turned to rapid but partially inadequate
41 methods for its evaluation.

42 **Materials and Methods:** The present study demonstrates a standardized, quantitative method to
43 assess phage virulence based on three parameters: the Virulence Index (V_P) – quantifying the
44 virulence of a phage against a host, the local virulence (v_i) – assessing killing potential at given
45 MOIs, and MV_{50} – the MOI at which the phage achieves 50% of its maximum theoretical virulence.
46 This was shown through comparative analysis of the virulence of phages T4, T5 and T7.

47 **Results:** Under the conditions tested, phage T7 displayed the highest virulence, followed by phage
48 T4 and, finally, phage T5. The impact of parameters such as temperature and medium composition
49 on virulence was shown for each phage. The use of the method to evaluate the virulence of
50 combinations of phages – e.g. for cocktail formulation – is also shown with phages T5 and T7.

51 **Conclusions:** The method presented provides a platform for high-throughput quantitative assessment
52 of phage virulence and quality control of phage products. It can also be applied to phage screening,
53 evaluation of phage strains, phage mutants, infection conditions and/or the susceptibility of host
54 strains, and the formulation of phage cocktails.

55

56 Introduction

57 Despite the significant impact bacteriophages (phages) have had in understanding genetic and
58 gene regulation¹, and the enormous estimated number of phages present on this planet², a relatively
59 small number of phage species have been identified and fewer have been fully characterized. But this
60 is rapidly changing. Initiatives have been launched to both isolate new phage species and annotate the
61 staggering amount of genomic data collected in the growing number of screening and
62 characterization studies (the PhAnToMe project, the Marine Phage Sequencing Project, and^{3,4} are
63 just some examples). There are also numerous ongoing efforts to identify phages suitable for phage
64 therapy⁵⁻⁸, biocontrol^{9,10}, prevention of biofilms¹¹⁻¹², detection and diagnostics¹³⁻¹⁵, and as active or
65 structural elements in biomaterials.^{16,17} With the rapidly growing number of applications comes an
66 increasing need for the manufacture of phages and phage products, and by extension approaches and
67 methods to reliably assess their efficacy and quality. As the efficacy of phage products relies on the
68 phage properties, in many ways assessment of quality is tied to phage characterization.

69 Several standardized growth-associated parameters are used to characterize phages. These
70 include burst size (virus particles produced per infection), eclipse period (period from infection to the
71 production of the first viable intracellular phage virion), latent period (period from infection to cell
72 lysis), adsorption rate, adsorption efficiency, and overall growth rate or ‘phage fitness,’ to name a
73 few. Together, these parameters all contribute to phage virulence, “the killing ability of the phage”,
74 but there is no standardized way to report, or even a clear definition of, phage virulence itself.

75 In epidemiology, a common measurement of virulence is the reproduction number (R_0) –
76 defined as the average number of additional hosts that the virus will spread to after infecting a single
77 host¹⁸. An equivalent measurement is not applicable to the virulent phage life cycle. The number of
78 phage progeny released per infected cell is given by the burst size; when replicating in a healthy,
79 densely growing bacterial culture, the R_0 of a phage is essentially equal to its burst size. However,
80 burst size alone is not a proper indicator of phage virulence. For example, in a study of the efficacy

81 of phage therapy, virulence was found to be an increasing function of both adsorption rate and burst
82 size.¹⁹ In fact, even more parameters are needed to fully quantify virulence; these include, amongst
83 others, the latent period, adsorption efficiency, and host cell growth rate.²⁰ In this context, virulence
84 can be defined as the ability of a phage to kill or damage a host population.²¹ As pointed out by
85 Hobbs and Abedon²², the concept of virulence is often applied to differentiate phages undergoing
86 lytic rather than lysogenic or chronic infections. But even in the case of comparing strictly lytic
87 phages or various clones of a strictly lytic phage, it is possible to infer different degrees of virulence,
88 despite the inconsistencies in terminology.

89 Common techniques employed to qualitatively measure virulence are spot tests on agar plates
90²³ and bacterial reduction curves.²⁴ A spot test entails spreading a small sample of a specific phage
91 over a bacterial culture growing in a top-agar lawn. This is a quick way to test susceptibility of a
92 bacterial strain to various phages but does not capture infection dynamics.²⁵ A bacterial reduction
93 curve is obtained by infecting a liquid bacterial culture with phages and taking periodic optical
94 density measurements, which will be reduced compared to those of a phage-free control. A typical
95 virulence study consists of generating bacterial reduction curves under various conditions and
96 qualitatively comparing which bacterial curve is ‘reduced’ the most. The advantage of this approach
97 is that it is applicable to any phage cultivable in suspended cultures. The disadvantages are that it is
98 time-consuming, non-standardized and only qualitative in its current incarnation. Examples of
99 bacterial reduction curves are plentiful in the literature.^{24,26-34} While all these experiments rely on the
100 same principle, no standardized or quantitative method has emerged to quantify virulence or facilitate
101 comparisons across conditions and studies.

102 In one study, four isolated phages specific to *Escherichia coli* O157:H7 were screened against
103 hundreds of *E. coli* strains to gather host range and susceptibility data.²⁴ The protocol consisted of
104 performing bacterial infections in 220- μ l volumes using 96-well plates. Bacterial cultures at the same
105 optical density were inoculated with phages at initial Multiplicities of Infection (MOIs) ranging from
106 10^{-6} to 10^2 . Plates were incubated at 37°C for 5 hours and then visually observed for signs of cell
107 lysis. Host cell susceptibility was then categorized based on the minimum MOI required to obtain a
108 culture-wide lysis by visual inspection. This approach offers many improvements over the current
109 mix of non-standardized protocols adopted by different researchers. But it has shortcomings. Firstly,
110 it relies on visual inspection rather than a measureable property. Secondly, it fails to capture the
111 dynamics of infection, instead relying on endpoint measurements, which can be misleading. Thirdly,
112 it defines lytic capability in terms of susceptibility of the host rather than the phage.

113 Another study introduced the concept of comparing the areas under bacterial infection curves to
114 non-infected bacterial growth curves was introduced as a means of evaluating the conditions at which
115 a phage or a combination of two phages was most efficient at killing its host (infective).³⁵ Recently,
116 Xie et al.³⁶ built on this concept to demonstrate how bacterial reduction curves performed in
117 microplates can be used for the high throughput evaluation of host range and phage infectivity. In the
118 study, the authors demonstrated how the comparison of the areas under the curves could be used to
119 semi-quantify the efficacy of a phage against a given host or a range of hosts.

120 In the present study, we detail a method to measure phage virulence that overcomes the
121 shortcomings faced by traditional methods. We build on the premise that comparisons between
122 infected and non-infected bacterial cultures can be used to quantitatively assess the virulence of a
123 phage or phage mixture – as demonstrated in^{35,36}. This method generates a Virulence Index (V_P) for a
124 phage infecting a specific host strain under a given set of environmental conditions. The present
125 study, which compares the virulence of phages T4, T5 and T7 under various conditions, shows the

126 Virulence Index can be used to easily compare and quantify the virulence of diverse phages. This
127 protocol greatly simplifies and improves the reliability of virulence measurements, and provides a
128 platform to quantitatively compare between phages and conditions.

129 The phage research community and industry require a simple, fast, and standardized way to
130 measure quantitatively phage virulence that takes into account all factors affecting virulence. This
131 will greatly facilitate screening, selection, comparison and quality control of phages and phage
132 products for specific scientific, industrial or therapeutic applications. Such a method can also be used
133 to monitor the impact of mutations or adaptation on virulence, and to establish formulations of phage
134 cocktails for various applications.

135

136 **Materials and Methods**

137 ***Organisms and Media***

138 Cultures of *Escherichia coli* ATCC 11303 used for experimentation were grown overnight in
139 10 ml of medium. The media used were Bacto Tryptic Soy Broth (TSB; Becton Dickinson, Sparks,
140 MD) and BBL Brain Heart Infusion (BHI; Becton Dickinson, Sparks, MD). Host cultures were
141 grown in 125-ml Erlenmeyer flasks containing 10 ml of medium, agitated at 150 rpm and incubated
142 at 37°C. Phage species used were phage T4 (ATCC 11303-B4), phage T5 (ATCC 11303-B5), and
143 phage T7 (ATCC 11303-B7). Phage stocks were stored at 4°C in TSB at titers of 4.5×10^8 pfu/ml,
144 2.3×10^8 pfu/ml, and 2.1×10^8 pfu/ml, respectively.

145 ***Bacterial Reduction Experiments***

146 Overnight cultures (100 μ l) were used to inoculate 10 ml of fresh medium in an Erlenmeyer
147 flask, incubated at 37°C and 150 rpm. These cultures were allowed to grow beyond the starting
148 bacterial concentration used for the bacterial reduction experiments (10^8 cfu/ml). All bacterial
149 reduction curves were generated using 96-well plates with 300- μ l well volumes. Phage stocks were
150 serially diluted from a concentration of 10^8 pfu/ml to 10 pfu/ml in 200- μ l volumes. Plates were
151 incubated at 37°C for 30 minutes prior to inoculation to ensure stable temperatures. Cell
152 concentrations were adjusted to 10^8 cfu/ml for every experiment, unless otherwise indicated, yielding
153 MOIs ranging from 10^{-7} to 1. In this report, MOI refers to the initial MOI at the initiation of phage
154 infection. Considering that the working volume used to generate the reduction curves was 250 μ L,
155 MOIs lower than 10^{-7} were not tested since, on average, they would have less than 1 phage per
156 culture. A layout of the microplate used for high throughput evaluation of virulence can be seen in
157 Fig. 1A. Four wells of phage-free bacterial cultures were included on every plate as control
158 experiments, in addition to four media-blanks for reference. Experiments were run with all phage
159 samples growing in parallel in a final volume of 250 μ l. Since phages are serially diluted to obtain
160 different MOIs, this set-up can be completed rapidly with a multichannel pipetter. Optical density
161 was measured at 630 nm with a Bio-Tek ELx800 Universal Microplate Reader and the data was
162 recorded using KCJunior software. Optical density measurements were taken immediately after
163 inoculation and then at regular intervals afterwards. Between samples, the plates were covered and
164 placed in an incubator shaker at 150 rpm at the specified experimental temperature (continuous
165 incubation and readings in an incubating plate-reader is also possible, even recommended when
166 available). Measurements were taken until the control cultures reached stationary phase. Once all
167 data was collected, areas underneath the optical density vs. time curves were calculated using the

168 trapezoid rule for each well, from the time of infection to the time corresponding to the onset of
169 stationary phase in the phage-free control.

170 ***Evaluation of Phage Cocktails***

171 The virulence of two combinations of phages T5 and T7 (at proportional T5:T7 ratios of 1:1 and 3:1)
172 was also assessed using the same procedure as described above, with the particularity that the MOI
173 reported was the combined MOI of both phages. For example, when the ratio of 1:1 was tested, 0.5×10^8
174 pfu/ml of phage T5 and 0.5×10^8 pfu/ml of phage T7 were used to make a total combined titer
175 of 1×10^8 pfu/ml, for an MOI of 1. Similarly, for the 3:1 ratio, 0.75×10^8 pfu/ml of phage T5 and
176 0.25×10^8 pfu/ml of phage T7 were used for a total combined titer of 1×10^8 pfu/ml. The use of the
177 combined MOI is important for the assessment of virulence in comparison to results with single
178 phages; this allows the rapid identification of synergistic or inhibitory effects between phages. In
179 these tests, the microplate layout described in Fig. 1A was still used, where triplicates of phage
180 cocktails occupied 3 columns. Incubation in TSB at 37°C, measurements and analysis were
181 conducted in the same manner as for single phage testing.

182 ***Statistical Analysis***

183 Virulence assays for each phage species were performed in duplicate on three separate micro-
184 well plates (n=6) or in triplicate in a single plate (n=3) for the comparison of phage cocktails. This
185 was done so that inaccurate readings or potential contamination could be detected. Data points on
186 graphs are shown as the average of all replicates; error bars depict the standard deviation. Errors
187 reported for Virulence Index (V_P – defined below) values are the summation of errors in all the local
188 virulence (v_i – defined below) values from which the V_P was determined.

189

190 **Results**

191 ***Virulence Protocol and Nomenclature***

192 The virulence measurements presented herein build on the premise of bacterial reduction
193 curves. A set of bacterial reduction curves – performed as described in the section above – for T4
194 infecting *E. coli* ATCC 11303 in TSB at 37°C is shown in Fig. 1B. The phage-free control exhibits a
195 classic growth pattern. As can be seen in the other curves found in Fig. 1B, the presence of the phage
196 can significantly reduce the presence of bacteria. By comparing the bacterial reduction curves to the
197 control, we can quantify the reduction due to the killing or damaging of the host by the phage. This is
198 done by comparing the integrated area of a bacterial reduction curve (A_i , where i is the MOI) to the
199 integrated area of the phage-free control (A_0) as shown in Fig. 1C for the MOI 10^{-3} . These areas are
200 calculated from the onset of infection (time 0) to the time of the onset of the stationary phase in the
201 phage-free control (indicated by the vertical dashed grey line near 3h in Fig. 1C). It is important to
202 stress how the establishment of the limit of integration plays a significant role in the assessment of
203 virulence. This limit should be set as the onset of stationary phase in the phage-free control (at 3h in
204 Fig. 1C). This provides a consistent reference for integration that can be easily identified for any
205 phage-host system and restricts measurements to the period of cell growth – a necessary condition for
206 productive infection for many phages.³⁷ Moreover, it ensures that the range of the virulence
207 measurements is well distributed no virulence and maximum virulence, as discussed below. In
208 general, we recommend establishing the limit of integration at the time when the slope of OD₆₀₀ over
209 time reaches $\leq 0.03 \text{ h}^{-1}$.

210 Using the two areas calculate for the free-phage control (A_o) and the culture infected at a given
211 MOI (A_i), a local virulence (v_i), capturing the dynamics of phage infection, can be calculated for that
212 specific MOI under a given set of conditions:

$$213 \quad v_i = 1 - \frac{A_i}{A_o} \quad (1)$$

214 where v_i reports the killing or damaging ability of the phage at a given MOI. The more virulent a
215 phage, the faster it kills a large number of bacteria (or prevents them from growing), and the greater
216 v_i . Local virulence is measured on a scale from 0 to 1, where 0 represents the absence of virulence
217 and 1 represents maximum theoretical virulence – instantaneous cell death. While this theoretical
218 maximum is unlikely to be observed in the laboratory, a v_i over 0.90 is readily achievable with the
219 appropriately lytic phage-host system.

220 Additionally, a virulence curve (Fig. 1E) can be obtained for the phage grown under a given
221 set of environmental conditions (e.g. temperature, medium, ionic strength) by plotting local
222 virulences calculated from Fig. 1B against $\log MOI$ (which is easily obtained from the conversion of
223 the MOI axis seen in Fig. 1D). This provides a powerful tool in characterizing a phage against a
224 specific host over a large range of MOIs. Generally, the earlier v_i approaches 1 on the virulence
225 curve, the more virulent the phage. Two important values can be gathered from such virulence curves
226 to quantify phage virulence: the Virulence Index (V_P , where P refers to the phage species) and MV_{50}
227 (MOI required to produce a local virulence of 0.5).

228 The Virulence Index is defined as the area under the virulence curve (A_P) divided by the
229 theoretical maximum area under the virulence curve (A_{max}):

$$230 \quad V_P = \frac{A_P}{A_{max}} \quad (2)$$

231 where A_P is determined by integrating the virulence curve according to:

$$232 \quad A_P = \int_{-7}^0 v_i d(\log MOI) \quad (3)$$

233 Note that $\log MOI$ is used in the integration in order to give equal weighting to each v_i when
234 calculating the Virulence Index. The value for A_{max} is determined by Eq. 3 under the special
235 condition that $v_i = 1$ for all MOIs. In this study, $A_{max} = 7$ for all conditions tested, since the range
236 of MOIs investigated goes from $\log MOI = -7$ to $\log MOI = 0$.

237 Similarly to the local virulence, the Virulence Index is normalized such that the theoretical
238 maximum is 1. To reach this value, instantaneous lysis of the entire bacterial culture for all MOIs
239 tested would be required, a physical impossibility. In this study, the highest Virulence Index
240 observed was 0.84. A Virulence Index of 0 signifies the complete absence of virulence over the range
241 of MOIs tested.

242 From the data shown in Fig. 1D (phage T4 in TSB at 37°C) a Virulence Index of 0.6 was
243 obtained. It was calculated as follows (integrations calculated using the trapezoid rule):

$$244 \quad A_{T4}(37^\circ\text{C}, \text{TSB}) = \int_{-7}^0 v_i d(\log MOI) = 4.2 \quad (4)$$

245 $V_{T4}(37^{\circ}\text{C}, \text{TSB}) = \frac{A_P}{A_{max}} = \frac{4.2}{7} = 0.6$ (5)

246 The final quantitative parameter given by the virulence curve is MV_{50} , an analog to ID_{50}
247 (infective dose for 50% of subjects) used in toxicology.³⁸ It is defined as follows:

248 $MV_{50} \equiv MOI|_{v_i=0.5}$ (6)

249 The MV_{50} is the MOI for which the local virulence v_i is equal to 0.5; the MOI at which the
250 phage achieves 50% of the maximum theoretical virulence. This provides another tool for comparing
251 phage virulence. The lower the MV_{50} , the more virulent the phage. The MV_{50} can be found through
252 inspection of the virulence curve. As an example, the MV_{50} for phage T4 at 37°C in TSB obtained
253 from Fig. 1D is:

254 $MV_{50}(T4, 37^{\circ}\text{C}, \text{TSB}) \equiv MOI|_{v_i=0.5} = 4 \times 10^{-5}$ (7)

255 Note that the MV_{50} should be reported to only one significant figure due to the intrinsic error in the
256 virulence curve. This measure is meant as a means of comparison of the order of magnitude of
257 virulence.

258 **Comparison of Virulence**

259 Bacterial reduction curves and their corresponding virulence curves are shown for phages T5
260 (Fig. 2A and 2B) and T7 (Fig. 2C and 2D) in TSB at 37°C.

261 Phage T5 was the least virulent phage studied (Fig. 2B). In contrast to the bacterial reduction
262 curves exhibited by phage T4 (Fig. 1D) and phage T7 (Fig. 2D), phage T5 only began to show
263 measurable virulence at MOIs $\geq 10^{-2}$. For all MOIs below this threshold, the values of local
264 virulence observed were 0 (Fig. 2A). Although being noticeable only from an MOI of 10^{-2} , the local
265 virulence increased rapidly, peaking at 0.8 at an MOI of 1. Accordingly, the Virulence Index
266 measured for T5 under the conditions tested was $V_{T5}(37^{\circ}\text{C}, \text{TSB}) = 0.17$.

267 Phage T7 was the most virulent phage tested under these conditions and yielded a Virulence
268 Index of 0.84 (from Fig. 2D). The remarkably virulent nature of this phage is observed qualitatively
269 in the bacterial reduction curves (Fig. 2C). At MOIs ranging from 1 to 10^{-3} , culture-wide lysis was
270 achieved within 1 h. Even at the lowest MOI tested (10^{-7}) culture-wide lysis was observed after 2.5 h;
271 whereas the phage-free control grew to stationary phase in 3 h (Fig. 2C).

272 While the virulence curves can be used to quickly and effectively compare different phages,
273 mutants or progeny, they also provide excellent visual tools for analysis and comparison of how a
274 phage behaves under a set of conditions. For example, Fig. 3 compares the virulence curves for
275 phages T4, T5, and T7 in different environmental conditions. It is clear from these curves that
276 temperature (Fig. 3A vs. 3B) and media composition (Fig. 3B vs. 3C) significantly impact phage
277 virulence. Importantly, the same range of MOIs must be used when comparing virulence across
278 different phage species or conditions. If virulence measurements were limited to MOIs ranging from
279 10^{-2} to 1, inspection of Fig. 3C would lead one to conclude that phages T4 and T7 have very similar
280 behaviours. However, inspection of the entire experimental range demonstrates significant
281 differences in the virulence between these phages.

282 Table 1 displays the Virulence Index (V_P) and MV_{50} values for phages T4, T5, and T7 in two
283 different media (TSB and BHI) at two different temperatures (30°C and 37°C). The data

284 demonstrates the full spectrum of virulence, from the limited virulence of phage T5 in BHI at 37°C
285 ($V_{T5} = 0.05$, $MV_{50} > 1$) to the exceptional virulence of T7 in TSB at 37°C ($V_{T7} = 0.84$, $MV_{50} <$
286 10^{-7}). Together the Virulence Index and the MV_{50} values provide a framework for assessing the
287 virulence of a phage and for comparing phage virulence across species and conditions.

288 Using the values calculated for phages T4, T5, and T7, it is a straightforward task to identify
289 the relative virulence of each phage. Phage T7 had the highest virulence values and lowest MV_{50}
290 values in all conditions tested. Phage T5 consistently had the lowest virulence and highest MV_{50}
291 values. The effect of media conditions on virulence is also apparent. For all phages, BHI unfailingly
292 resulted in lower virulence values. However, the effect of temperature, over the admittedly narrow
293 range tested, was more muted. For phage T4, no significant effect of temperature on virulence was
294 seen between 30°C and 37°C. For T7, virulence increased with temperature, while it decreased for
295 T5.

296 *Evaluation of combinations of phages*

297 Similarly, the virulence curves for the mixtures of phages T5 and T7 provide information on
298 the performance of combinations of phages or of phage cocktails. As can be observed in Figure 4, the
299 reduction curves of the combinations of phages (ratios of phage T5 to T7 of 1:1 and 3:1) demonstrate
300 a killing potential between those of the single phages, with the 1:1 ratio showing more virulence.
301 This is also observed in the resulting values of virulence index (0.81 and 0.72, respectively) and
302 MV_{50} (5×10^{-6} and 1×10^{-6} , respectively). It is interesting to note that the Virulence Indexes obtained
303 are not proportional to the relative initial abundance of each phage in the cocktail. This is consistent
304 with the fact that, in the absence of interference or inhibition between them, the contributions of
305 individual phages in a cocktail depend on their individual infection kinetic parameters.

306

307 **Discussion**

308 Unlike most other biologics, phages are intrinsically dynamic in nature, be it through mutations
309 ³⁹⁻⁴³ or phenotypic traits.⁴³⁻⁴⁶ In addition, infections are influenced by many factors, some correlated,
310 others orthogonal, but all affecting infection dynamics. The evaluation of single parameters (e.g. titer,
311 burst size, efficacy of plating, etc.) is not sufficient. Generally, individual phage characteristics are
312 measured and discussed in relation to how they affect virulence.^{19,40,47} For example, faster adsorption
313 rates, larger burst sizes, and shorter latent periods are all conditions observed to increase phage
314 virulence. But there is no current way of relating these parameters or weighing their individual or
315 combined input towards an overall phage virulence. Hence, the characterization of phages, the
316 evaluation of their efficacy and quality control through the manufacturing process all require a
317 different approach, one that encompasses the effects of all factors influencing virulence.

318 As mentioned above, researchers have been using qualitative observations of bacterial
319 reduction curves to describe phage virulence for many years. In fact, groups have proposed a cell
320 susceptibility scale based on visual observations of the bacterial reduction curve²⁴ and a primary
321 comparison of the area under reduction curves.^{35,36} The Virulence Index and MV_{50} measurements
322 forego these limitations and enable direct, quantitative comparisons of phage virulence,
323 compounding all the parameters affecting it.

324 The local virulence and Virulence Index are valuable tools for screening new phage isolates
325 and comparing phages for specific applications. Consider the case of the bacterial reduction curve for

326 phage T7 at an MOI of 10^{-7} (Fig. 2C). It achieved a local virulence value of $v_{10^{-7}} = 0.62$, and
327 complete lysis of the culture occurred within 2 hours; astonishingly fast considering such a low MOI.
328 In fact, the virulence curve (Fig. 2D) begins at this value and increases steadily before stabilizing
329 above 0.9 for MOIs $\geq 10^{-3}$. Therefore, for T7, the MV_{50} is less than 10^{-7} . In contrast, for phage T5
330 under the same conditions, the MV_{50} was 10^{-1} – over 6 orders of magnitude larger than for phage T7.
331 In order to achieve the same lytic capability as one phage T7, more than 1 million phage T5 virions
332 are required at the onset of infection.

333 An important consideration when comparing local virulence, Virulence Index, and MV_{50}
334 values among various phages and/or conditions is that these parameters are indirect measurements of
335 infection dynamics. Since they are calculated based on the relationship between infected cultures and
336 the growth of the host, they serve as quantitative descriptors of the effect of phages on cell cultures.
337 They are impacted by all the environmental and physiological factors influencing the host and/or
338 phage growth and propagation rates. Thus even if infections may be slower at one set of conditions
339 compared to another (due to slower adsorption rates, longer lysis times, or smaller burst sizes), if the
340 growth of the host is also slowed down by the same magnitude, the virulence may remain the same.
341 This is a powerful aspect of these measurements: they reflect kinetics without being impeded by
342 them.

343 Phage virulence is thus affected by a large number of environmental and physiological
344 parameters. For example, conditions such as temperature, pH, media composition, and aeration can
345 all affect both host cell growth rate – influencing phage growth-associated parameters such as burst
346 size and latent period – and phage adsorption rate – affecting the rate of infection.³⁷ Moreover, phage
347 infections at the population level can exhibit characteristics not easily observed in individual host-
348 phage interactions (e.g. lysis inhibition in the case of T4). All these interacting variables contribute to
349 virulence. A recent study testing the efficacy of six newly isolated phages to treat *Pseudomonas*
350 *aeruginosa* infection of *Drosophila melanogaster* found no correlation between burst size, adsorption
351 rate, or latent period and phage therapy efficacy.⁴⁷ The only phage parameter found to correlate
352 significantly with treatment efficacy was phage growth rate – implying that a measurement of phage
353 virulence needs to account for contributions of all the disparate factors working together.

354 With the introduction of the Virulence Index, there now exists a metric which can be used to
355 quantify the pooled contribution of each of these variables on overall phage virulence. Which
356 features of phages T4, T5 and T7 lead to such significant differences in virulence when infecting *E.*
357 *coli* in TSB? Phage T4 has a very high adsorption rate and adsorption efficiency in TSB⁴⁸, while T5
358 and T7 both have similar adsorption rates with poor adsorption efficiencies in the same medium.⁴⁹
359 Perhaps this poor adsorption efficiency is a major reason why T5 displays limited virulence in TSB.
360 Yet, T7, which has even lower adsorption efficiency, is extremely virulent. In this case, the latent
361 period and/or burst size may be the deciding factors. While not measured in these experiments, T7 is
362 reported to exhibit latent periods of less than 20 minutes while T5's latent period can exceed 40
363 minutes.⁵⁰ Note that the relative importance of each of these parameters in determining virulence may
364 also be influenced by the bacterial cell density. The virulence curve can be used in conjunction with
365 traditional measurements of phage growth kinetics to determine the contribution each phage growth
366 parameter has on overall phage virulence.

367 In addition, as highlighted by many studies⁵¹⁻⁵⁴, the formulation of phage cocktails is crucial
368 to the success of many phage-based treatments and technologies. Considering most cocktails are
369 composed of more than two phages, proper optimization studies require testing vast numbers of
370 possible formulations, which can be difficult and time-consuming. Hence, it would be most practical

371 to perform a large number of comparisons at a given MOI on a single multi-plate; essentially
372 comparing the values of local virulence (v_l) for various combinations of phages. In this case, the
373 whole multi-plate layout could be modified to have various formulations all at the same MOI (rather
374 than the range of MOIs described and shown in Fig. 1). On the other hand, the Virulence Index and
375 the shape of the virulence curve (Fig. 4) can also be used to further understand some of the
376 interactions between the individual phages making up the cocktail. For example, to see if the
377 presence of a phage in the cocktail impedes on the overall virulence.

378

379 **Conclusion**

380 The developed methodology will facilitate and standardize the important screening steps used
381 in selecting a phage for specific applications. It can also be used to benchmark different phages or
382 production batches for consistency and quality control purposes, or serve as a reliable comparison
383 platform in the elaboration of formulation of phage cocktails. Finally, it can easily be integrated in
384 high throughput strategies, a non-negligible factor as phage isolation and screening efforts are rapidly
385 expanding.

386

387 **Acknowledgements**

388 Funding for this research was provided by the Natural Sciences and Engineering Research Council of
389 Canada, Alberta Innovates Technology Futures and the University of Alberta Research Experience
390 program. Special thanks to Melissa Harrison who performed the assays for the combinations of T5-
391 T7.

392

393 **Authorship Confirmation Statement**

394 ZS and DS designed experiments. ZS, MRT, and KM performed experiments and analyzed data. ZS,
395 MRT, and DS developed virulence metrics. ZS, MRT, and DS wrote the manuscript.

396

397 **Author Disclosure Statement**

398 No competing financial interests exist.

399

400 **References**

401 [1] Ptashne M. *A genetic switch: phage lambda revisited*. Cold Spring Harbor: Cold Spring Harbor
402 Laboratory Press; 2004.

403 [2] Abedon ST. (Ed.) *Bacteriophage Ecology: Population Growth, Evolution, and Impact of*
404 *Bacterial Viruses*. Cambridge, UK: Cambridge University Press; 2008.

- 404 [3] Hatfull GF. Dark matter of the biosphere: the amazing world of bacteriophage diversity. *J. Virol.*
405 2015;89:8107-8110.
- 406 [4] Hatfull GF. Innovations in undergraduate science education: going viral. *J. Virol.* 2015; 89:8111-
407 8113.
- 408 [5] Merabishvili M, Pirnay JP, Verbeken G et al. Quality-controlled small-scale production of a well-
409 defined bacteriophage cocktail for use in human clinical trials. *Plos One* 2009;4:e4944.
- 410 [6] Rhoads DD, Wolcott RD, Kuskowski MA, et al. Bacteriophage therapy of venous leg ulcers in
411 humans: results of a phase I safety trial. *J. Wound Care* 2009;18:237-243.
- 412 [7] Pirnay JP, De Vos D, Verbeken G, et al. The phage therapy paradigm: pret-a-porter or sur-
413 mesure? *Pharm. Res.* 2011;28:934-937.
- 414 [8] Pirnay JP, Verbeken G, Rose T, et al. Introducing yesterday's phage therapy in today's medicine.
415 *Future Virol.* 2012;7:379-390.
- 416 [9] Jones JB, Jackson LE, Balogh B, et al. Bacteriophages for plant disease control. *Annu. Rev.*
417 *Phytopathol.* 2007;45:245-262.
- 418 [10] Mahony J, McAuliffe O, Ross RP, et al. Bacteriophages as biocontrol agents of food pathogens.
419 *Curr. Opin. Biotech.* 2011;22:157-163.
- 420 [11] Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. *P. Natl. Acad.*
421 *Sci. USA* 2007;104:11197-11202.
- 422 [12] Carson L, Gorman SP, Gilmore BF. The use of lytic bacteriophages in the prevention and
423 eradication of biofilms of *Proteus mirabilis* and *Escherichia coli*. *FEMS Immunol. Med. Mic.*
424 2010;59:447-455.
- 425 [13] Huang S, Yang H, Lakshmanan RS, et al. The effect of salt and phage concentrations on the
426 binding sensitivity of magnetoelastic biosensors for *Bacillus anthracis* detection. *Biotechnol.*
427 *Bioeng.* 2008;101:1014-1021.
- 428 [14] Tawil N, Sacher E, Mandeville R, et al. Surface plasmon resonance detection of *E. coli* and
429 methicillin-resistant *S. aureus* using bacteriophages. *Biosens. Bioelectron.* 2012;37:24-29.
- 430 [15] Singh A, Poshtiban S, Evoy S. Recent advances in bacteriophage based biosensors for food-
431 borne pathogen detection. *Sensors (Basel)* 2013;13:1763-1786.
- 432 [16] Dang X, Yi H, Ham MH, et al. Virus-templated self-assembled single-walled carbon nanotubes
433 for highly efficient electron collection in photovoltaic devices. *Nat. Nanotech.* 2011;6:377-384.
- 434 [17] Pearson HA, Sahukhal GS, Elasri MO, et al. Phage-bacterium war on polymeric surfaces: can
435 surface-anchored bacteriophages eliminate microbial infections? *Biomacromol.* 2013;14:1257-
436 1261.
- 437 [18] Dietz K. The estimation of the basic reproduction number for infectious diseases. *Stat. Meth.*
438 *Med. Res.* 1993;2:23-41.

- 439 [19] Levin BR, Bull JJ. Phage therapy revisited: The population biology of a bacterial infection and
440 its treatment with bacteriophage and antibiotics. *Am. Nat.* 1996;147:881-898.
- 441 [20] Santos SB, Carvalho C, Azeredo J, et al. Population dynamics of a *Salmonella* lytic phage and
442 its host: implications of the host bacterial growth rate in modelling. *Plos One* 2014;9:e102507.
- 443 [21] Smith HW, Huggins MB, Shaw KM. The control of experimental *Escherichia coli* diarrhoea in
444 calves by means of bacteriophages. *J. Gen. Microbiol.* 1987;133:1111–1126.
- 445 [22] Hobbs Z, Abedon ST. Diversity of phage infection types and associated terminology: the
446 problem with ‘Lytic or Lysogenic’. *FEMS Microbiol. Lett.* 2016;363:fnw047.
- 447 [23] Kutter E. Phage host range and efficiency of plating, in: Clokie, M.R.J., Kropinski, A.M. (Eds.),
448 *Bacteriophages: Methods and Protocols* New York, NY: Humana Press; 2009.
- 449 [24] Niu YD, Johnson RP, Xu Y, et al. Host range and lytic capability of four bacteriophages against
450 bovine and clinical human isolates of Shiga toxin-producing *Escherichia coli* O157:H7. *J. Appl.*
451 *Microbiol.* 2009;107:646-656.
- 452 [25] Kropinski AM, Waddell T, Meng J, et al. The host-range, genomics and proteomics of
453 *Escherichia coli* O157:H7 bacteriophage rV5. *Viol. J.* 2013;10:76.
- 454 [26] Raya RR, Varey P, Oot RA, et al. Isolation and characterization of a new T-even bacteriophage,
455 CEV1, and determination of its potential to reduce *Escherichia coli* O157:H7 levels in sheep.
456 *Appl. Environ. Microbiol.* 2006;72:6405-6410.
- 457 [27] Vandersteegen K, Mattheus W, Ceysens PJ, et al. Microbiological and molecular assessment of
458 bacteriophage ISP for the control of *Staphylococcus aureus*. *Plos One* 2011;6:e24418.
- 459 [28] Niu YD, Stanford K, Ackermann HW, et al. Characterization of 4 T1-like lytic bacteriophages
460 that lyse Shiga-toxin *Escherichia coli* O157:H7. *Can. J. Microbiol.* 2012;58:923-927.
- 461 [29] Niu YD, Stanford K, Kropinski AM, et al. Genomic, proteomic and physiological
462 characterization of a T5-like bacteriophage for control of Shiga toxin-producing *Escherichia coli*
463 O157:H7. *Plos One* 2012;7:e34585.
- 464 [30] Vandersteegen K, Kropinski AM, Nash JH, et al. Romulus and Remus, two phage isolates
465 representing a distinct clade within the Twortlikevirus genus, display suitable properties for phage
466 therapy applications. *J. Virol.* 2013;87:3237-3247.
- 467 [31] Chaudhry WN, Haq IU, Andleeb S, et al. Characterization of a virulent bacteriophage LK1
468 specific for *Citrobacter freundii* isolated from sewage water. *J. Basic Microbiol.* 2014;54:531-
469 541.
- 470 [32] Niu YD, McAllister TA, Nash JH, et al. Four *Escherichia coli* O157:H7 phages: a new
471 bacteriophage genus and taxonomic classification of T1-like phages. *Plos One* 2014;9:e100426.
- 472 [33] Saussereau E, Vachier I, Chiron R, et al. Effectiveness of bacteriophages in the sputum of cystic
473 fibrosis patients. *Clin. Microbiol. Infect.* 2014;20:O983-990.

- 474 [34] Wong CL, Sieo CC, Tan WS, et al. Evaluation of a lytic bacteriophage, Phi st1, for biocontrol of
475 *Salmonella enterica* serovar Typhimurium in chickens. *Int. J. Food Microbiol.* 2014;172:92-101.
- 476 [35] Bertozzi Silva J, Sauvageau D. Bacteriophages as antimicrobial agents against bacterial
477 contaminants in yeast fermentation processes. *Biotech. Biofuels* 2014;7:123.
- 478 [36] Xie Y, Wahab L, Gill JJ. Development and validation of a microtiter plate-based assay for
479 determination of bacteriophage host range and virulence. *Viruses* 2018;10:189.
- 480 [37] Adams MH. *Bacteriophages*. New York , NY: Interscience Publishers; 1959.
- 481 [38] Kato T, Kurashige S, Chabbert YA, et al. Determination of the ID50 values of antibacterial
482 agents in agar. *J. Antibiot.* 1978;31:1299-1303.
- 483 [39] Josslin R. The lysis mechanism of phage T4: Mutants affecting lysis. *Virology.* 1970;40:719-
484 726.
- 485 [40] Daniels LL, Wais AC. Virulence in phage populations infecting *Halobacterium cutirubrum*.
486 *FEMS Microbiol. Ecol.* 1998;25.
- 487 [41] Bronson MJ, Levine M. Virulent mutants of phage P22: II. Physiological analysis of P22 virB-3
488 and its component mutations. *Virology* 1972; 47:644-655.
- 489 [42] Storms ZJ, Sauvageau D. Evidence that the heterogeneity of a T4 population is the result of
490 heritable traits. *PLoSone* 2014;9:e116235.
- 491 [43] Ceysens P-J, Glonti T, Kropinski AM, et al. Phenotypic and genotypic variations within a
492 single bacteriophage species. *Virol. J.* 2011;8:134.
- 493 [44] Abedon ST. Communication among phages, bacteria, and soil environments. In: Witzany G.
494 (Ed.), *Biocommunication in Soil Microorganisms, Soil Biology* Vol. 23. Berlin, Germany:
495 Springer; 2011:37-65.
- 496 [45] Maxwell CS. Hypothesis: A plastically-produced phenotype predicts host specialization and can
497 precede subsequent mutations in bacteriophage. *bioRxiv* 2018;doi:10.1101/411983.
- 498 [46] Pagliarini S, Korobeinikov A. A mathematical model of marine bacteriophage evolution. *R. Soc.*
499 *Open Sci.*, 2018;5:171661.
- 500 [47] Lindberg H, McKean KA, Wang IN. Phage fitness may help predict phage therapy efficacy.
501 *Bacteriophage* 2014;4:e964081.
- 502 [48] Storms ZJ, Arsenault E, Sauvageau D, et al. Bacteriophage adsorption efficiency and its effect
503 on amplification. *Bioproc. Biosys. Eng.* 2010;33:823-831.
- 504 [49] Storms ZJ, Smith L, Sauvageau D, et al. Modeling bacteriophage attachment using adsorption
505 efficiency. *Biochem. Eng. J.* 2012;64:22-29.
- 506 [50] Foster RA, Johnson FH. Influence of urethane and of hydrostatic pressure on the growth of
507 bacteriophages T2, T5, T6, and T7. *J. Gen. Physiol.* 1951;34:529-550.

- 508 [51] Mendes JJ, Leandro C, Mottola C, et al. *In vitro* design of a novel lytic bacteriophage cocktail
509 with therapeutic potential against organisms causing diabetic foot infections. *J. Med. Microbiol.*
510 2014;63:1055-1065.
- 511 [52] Malik DJ, Sokolov IJ, Vinner GK, et al. Formulation, stabilization and encapsulation of
512 bacteriophage for phage therapy. *Adv. Coll. Interf. Sci.* 2017;249:100-133.
- 513 [53] Forti F, Roach DR, Cafora M, et al. Design of a broad-range bacteriophage cocktail that reduces
514 *Pseudomonas aeruginosa* biofilms and treats acute infections in two animal models. *Antimicrob.*
515 *Agents. Chemother.* 2018;62:e02573-17.
- 516 [54] Cooper CJ, Koonjan S, Nilsson AS. Enhancing whole phage therapy and their derived
517 antimicrobial enzymes through complex formulation. *Pharmaceuticals*, 2018;11:34.
- 518

TABLE

Table 1: Virulence and MV_{50} values for phages T4, T5, T7, and combinations of phages T5 and T7 under various conditions.

Phage	Virulence Index (V_P)				MV_{50}			
	30° C		37° C		30° C		37° C	
	TSB	BHI	TSB	BHI	TSB	BHI	TSB	BHI
T4	0.55	0.45	0.60	0.47	1×10^{-4}	1×10^{-3}	4×10^{-5}	6×10^{-4}
T5	0.28	0.05	0.17	0.01±	5×10^{-1}	> 1	1×10^{-1}	> 1
T7	0.77	0.69 ±	0.84	0.76	8×10^{-7}	6×10^{-7}	$< 10^{-7}$	4×10^{-6}
T5:T7 _(1:1)	-	-	0.81	-	-	-	5×10^{-6}	-
T5:T7 _(3:1)	-	-	0.72	-	-	-	1×10^{-6}	-

1 **FIGURE LEGENDS**

2

3 **Figure legends**

4 **Figure 1. A)** Layout of multi-plate for high throughput evaluation of virulence. Column 1 is used for
5 controls: green wells for phage-free cultures, gray wells for media blanks. Each column is used to test
6 a different phage. Rows indicate different initial MOIs, from 1 (row A) to 10^{-7} (row H). **B)** Bacterial
7 reduction curves for phage T4 infecting *E. coli* 11303 in TSB at 37°C. **C)** Growth curve of phage-
8 free control and bacterial reduction curve at MOI 10^{-3} (extracted from B). The dashed vertical line
9 indicates the limit of integration. **D)** Virulence curve generated from bacterial reduction curves of
10 phage T4 growing in TSB at 37°C. Each individual data point represents the local virulence (v_i) at
11 the corresponding MOI. Dotted line highlights MV50 determination. **E)** Virulence curve from D)
12 with x-axis converted to $\log_{10}(\text{MOI})$. Error bars depict the standard deviation of six replicates.

13

14 **Figure 2. A)** Bacterial reduction curves and **B)** corresponding virulence curve for phage T5 infecting
15 *E. coli* 11303 in TSB at 37°C. **C)** Bacterial reduction curves and **D)** corresponding virulence curve
16 for phage T7 infecting *E. coli* 11303 in TSB at 37°C. Error bars depict the standard deviation of six
17 replicates.

18

19 **Figure 3.** Virulence curves of phages T4, T5, and T7 in **A)** BHI at 30°C, **B)** BHI at 37°C, and **C)** in
20 TSB at 37°C. Error bars depict the standard deviation of six replicates.

21

22 **Figure 4.** Virulence curves of phages T5 (diamonds), T7 (squares), and combinations of phage T5
23 and T7 (3:1, circles; 1:1, triangles) in TSB at 37°C. Error bars depict the standard deviation of
24 triplicates.

25






FIGURE 1


A)



B)



C)



D)




FIGURE 2




FIGURE 3




FIGURE 4